Total Payments
$11,592
2023 Payments
$987.23
Companies
30
Transactions
148
Medicare Patients
33,911
Medicare Billing
$6.2M
Payment Breakdown by Category
Research$6,597 (56.9%)
Other$3,000 (25.9%)
Food & Beverage$1,624 (14.0%)
Education$370.96 (3.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6,597 | 55 | 56.9% |
| Honoraria | $3,000 | 1 | 25.9% |
| Food and Beverage | $1,624 | 80 | 14.0% |
| Education | $370.96 | 12 | 3.2% |
Payments by Type
Research
$6,597
55 transactions
General
$4,995
93 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $6,597 | 55 | $0 (2023) |
| Sirtex Medical Inc | $3,402 | 5 | $0 (2023) |
| Seagen Inc. | $191.95 | 2 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $159.74 | 11 | $0 (2017) |
| Genentech USA, Inc. | $150.13 | 14 | $0 (2018) |
| Seattle Genetics, Inc. | $125.66 | 4 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $122.49 | 8 | $0 (2017) |
| Regeneron Healthcare Solutions, Inc. | $98.15 | 1 | $0 (2019) |
| PFIZER INC. | $88.90 | 6 | $0 (2023) |
| Celgene Corporation | $70.81 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $987.23 | 13 | Regeneron Pharmaceuticals, Inc. ($842.79) |
| 2022 | $2,000 | 17 | Regeneron Pharmaceuticals, Inc. ($2,000) |
| 2021 | $2,627 | 21 | Regeneron Pharmaceuticals, Inc. ($2,507) |
| 2020 | $4,348 | 12 | Sirtex Medical Inc ($3,000) |
| 2019 | $258.66 | 8 | Seattle Genetics, Inc. ($125.66) |
| 2018 | $186.30 | 4 | Sirtex Medical Inc ($107.79) |
| 2017 | $1,185 | 73 | Sirtex Medical Inc ($191.22) |
All Payment Transactions
148 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/17/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $121.22 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 07/27/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2023 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $103.28 | General |
| Category: Interventional Oncology | ||||||
| 04/28/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $28.11 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 04/20/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $121.22 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 03/15/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $28.11 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/19/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $102.29 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/20/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $107.67 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/20/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $47.86 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/13/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $136.45 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/12/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $102.29 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/10/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $47.57 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/18/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $26.97 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/15/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $26.97 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/05/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $26.97 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 11/03/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $149.44 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/24/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $26.97 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/20/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $112.78 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/07/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $112.78 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/23/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $25.43 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/23/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $25.43 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/21/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $25.62 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/09/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $349.37 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/09/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $349.37 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $6,597 | 55 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 72 | 6,711 | 47,964 | $3.1M | $895,414 |
| 2022 | 76 | 7,867 | 95,067 | $3.5M | $957,927 |
| 2021 | 90 | 8,992 | 137,878 | $6.8M | $1.8M |
| 2020 | 108 | 10,341 | 202,516 | $10.1M | $2.6M |
Total Patients
33,911
Total Services
483,425
Medicare Billing
$6.2M
Procedure Codes
346
All Medicare Procedures & Services
346 procedure records from CMS Medicare Utilization — Page 1 of 14
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 21 | 8,800 | $1.1M | $378,896 | 35.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 435 | 1,045 | $319,770 | $90,320 | 28.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 156 | 610 | $250,710 | $77,030 | 30.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 20 | 3,300 | $161,700 | $57,531 | 35.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 646 | 2,621 | $86,493 | $27,022 | 31.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 107 | 299 | $149,799 | $25,540 | 17.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 675 | 2,894 | $66,562 | $21,891 | 32.9% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 13 | 1,300 | $63,700 | $21,368 | 33.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 661 | 2,497 | $43,550 | $20,959 | 48.1% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 379 | 1,082 | $63,838 | $19,939 | 31.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 194 | 244 | $50,752 | $14,157 | 27.9% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 242 | 594 | $38,610 | $11,997 | 31.1% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 38 | 1,830 | $95,160 | $10,762 | 11.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 75 | 174 | $36,366 | $10,043 | 27.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 59 | 66 | $38,412 | $8,410 | 21.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 55 | 55 | $32,120 | $8,406 | 26.2% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 145 | 429 | $21,021 | $7,061 | 33.6% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 248 | 437 | $18,354 | $5,804 | 31.6% |
| 82533 | Cortisol (hormone) measurement, total | Office | 2023 | 40 | 340 | $17,340 | $5,430 | 31.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 114 | 476 | $28,560 | $4,935 | 17.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 34 | 115 | $28,060 | $4,753 | 16.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 37 | 52 | $15,548 | $4,391 | 28.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 60 | 105 | $26,880 | $4,315 | 16.1% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 78 | 430 | $9,030 | $3,882 | 43.0% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 11 | 257 | $27,499 | $3,769 | 13.7% |
About Dr. Rhonda Gentry, MD
Dr. Rhonda Gentry, MD is a Specialist healthcare provider based in Little Rock, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/05/2007. The National Provider Identifier (NPI) number assigned to this provider is 1891834016.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rhonda Gentry, MD has received a total of $11,592 in payments from pharmaceutical and medical device companies, with $987.23 received in 2023. These payments were reported across 148 transactions from 30 companies. The most common payment nature is "" ($6,597).
As a Medicare-enrolled provider, Gentry has provided services to 33,911 Medicare beneficiaries, totaling 483,425 services with total Medicare billing of $6.2M. Data is available for 4 years (2020–2023), covering 346 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Hematology & Oncology
- Location Little Rock, AR
- Active Since 02/05/2007
- Last Updated 03/30/2022
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1891834016
Products in Payments
- LIBTAYO (Biological) $6,695
- SIR-Spheres Microspheres (Device) $3,402
- ADCETRIS (Biological) $125.66
- KEYTRUDA (Biological) $72.66
- Revlimid (Drug) $70.81
- JADENU (Drug) $64.47
- GAZYVA (Biological) $52.91
- FOUNDATIONONE (Device) $50.47
- EMEND (Drug) $49.83
- IBRANCE (Drug) $48.81
- Neulasta (Biological) $47.08
- Lenvima (Drug) $46.17
- ELIQUIS (Drug) $45.63
- Imbruvica (Drug) $39.70
- GILOTRIF (Drug) $35.67
- VENCLEXTA (Biological) $32.92
- AFINITOR (Drug) $30.04
- XARELTO (Drug) $26.57
- TECENTRIQ (Biological) $26.45
- JAKAFI (Drug) $26.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Little Rock
Dr. Samuel Bledsoe, M.d, M.D
Specialist — Payments: $52,552
Specialist $52,552
Dr. Scott Schlesinger, Md, MD
Specialist — Payments: $35,349
Specialist $35,349
Dr. Joe Bradley, M.d, M.D
Specialist — Payments: $32,732
Specialist $32,732
Dr. Brad Baltz, Md, MD
Specialist — Payments: $27,257
Specialist $27,257
Dr. Michael Johnson, Md, MD
Specialist — Payments: $18,114
Specialist $18,114
Dr. Joseph Beck, Md, MD
Specialist — Payments: $14,225
Specialist $14,225